JNJ catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
Windows longer than 90 days are part of TrialScanner, so this list covers the next 90 days.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 19, 2026Sponsor estimate | NCT07230860A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic DermatitisJanssen Research & Development, LLC · Dermatitis, Atopic | JNJLead | Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Nov 23, 2026Sponsor estimate | NCT07735793A Real-world Study in Participants With High-risk Non-Muscle-Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy in KoreaJanssen Korea, Ltd., Korea · Urinary Bladder Neoplasms | JNJLead | No phase registered | Recruiting | Locked | Locked | Locked |
| Nov 30, 2026Sponsor estimate | NCT07680907A Real World Study of Participants With Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor Mutation (EGFRm)Janssen-Cilag Farmaceutica Ltda. · Carcinoma, Non-Small-Cell Lung | JNJLead | No phase registered | Not yet recruiting | Locked | Locked | Locked |
- Primary completion Nov 19, 2026Sponsor estimatePhase 2NCT07230860A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic DermatitisJanssen Research & Development, LLC · Dermatitis, AtopicActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 23, 2026Sponsor estimateNo phase registeredNCT07735793A Real-world Study in Participants With High-risk Non-Muscle-Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy in KoreaJanssen Korea, Ltd., Korea · Urinary Bladder NeoplasmsRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT07680907A Real World Study of Participants With Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor Mutation (EGFRm)Janssen-Cilag Farmaceutica Ltda. · Carcinoma, Non-Small-Cell LungNot yet recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 1, 2026Sponsor estimatePhase 3NCT03767244A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical...Janssen Research & Development, LLC · Prostatic NeoplasmsActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 8, 2026Sponsor estimatePhase 1NCT04644770A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate CancerJanssen Research & Development, LLC · Prostatic NeoplasmsActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 8, 2026Sponsor estimatePhase 3NCT05757869A Study of Milvexian Versus Apixaban in Participants With Atrial FibrillationJanssen Research & Development, LLC · Atrial FibrillationActive, not recruitingJNJLeadBMYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 10, 2026Sponsor estimateNo phase registeredNCT02808780An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative ColitisJanssen Biotech, Inc. · Ulcerative ColitisActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 2/Phase 3NCT05327114Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Janssen Research & Development, LLC · Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 15, 2026Sponsor estimatePhase 1NCT07223125A Study of JNJ-89862175 for Treatment of Advanced Solid TumorsJanssen Research & Development, LLC · Advanced-stage Solid TumorsRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 22, 2026Sponsor estimatePhase 2NCT06544616A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's DiseaseJanssen Pharmaceutica N.V., Belgium · Alzheimer DiseaseActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 3NCT04658862A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder...Janssen Research & Development, LLC · Urinary Bladder NeoplasmsActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2026Sponsor estimatePhase 3NCT06559306Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia...Janssen Research & Development, LLC · Depressive Disorder, MajorRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 3NCT01804686A Long-term Extension Study of PCI-32765 (Ibrutinib)Janssen Research & Development, LLC · Chronic Lymphocytic LeukemiaActive, not recruitingJNJLeadABBVCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT02609776Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung CancerJanssen Research & Development, LLC · Non-Small-Cell Lung CancerActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT04662580ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate CancerJanssen Research & Development, LLC · Metastatic Prostate CancerActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
- Primary completion Jan 6, 2027Sponsor estimatePhase 1NCT05784441A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)Janssen Research & Development, LLC · Relapsed or Refractory B Cell Non-Hodgkin LymphomaActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 7, 2027Sponsor estimatePhase 1NCT07319871A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate CancerJanssen Research & Development, LLC · Prostatic NeoplasmsRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2027Sponsor estimatePhase 3NCT05179876A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionActelion · Hypertension, PulmonaryRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2027Sponsor estimatePhase 1/Phase 2NCT05908734A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung CancerJanssen Research & Development, LLC · Carcinoma, Non-Small-Cell LungActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
February 2027
- Primary completion Feb 4, 2027Sponsor estimatePhase 3NCT06741969Nipocalimab in Moderate to Severe Sjogren's DiseaseJanssen Research & Development, LLC · Sjogrens SyndromeActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 10, 2027Sponsor estimatePhase 3NCT06260163A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative ColitisJanssen Research & Development, LLC · Colitis, UlcerativeActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 10, 2027Sponsor estimatePhase 3NCT06807424A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With...Janssen Research & Development, LLC · Arthritis, PsoriaticActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 12, 2027Sponsor estimatePhase 1NCT04077463A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung CancerJanssen Research & Development, LLC · Carcinoma, Non-Small-Cell LungActive, not recruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 16, 2027Sponsor estimatePhase 1NCT07669077A Study to Assess Nipocalimab Concentrations in Breast Milk of Healthy Lactating WomenJanssen Research & Development, LLC · HealthyRecruitingJNJLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 24 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.